Osteoporosis affects approximately 75 million people worldwide. Because of limitations in the widely accepted screening guidelines (especially for men), the number of individuals affected with osteoporosis is probably underestimated.
This article reviews the epidemiology of osteoporosis, as well as the risk factors for its development, as illustrated by the case of a 71 year old smoker and COPD patient. It further reviews the screening guidelines for men including special populations of men, such as those undergoing androgen deprivation therapy, and concludes with a discussion of treatment options. Finally there is a detailed discussion of the case resolution.
FrostM., AbrahamsenB., NielsenTL. HagenC., AndersenM., BrixenK.Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism. Clin Endocrinol (Oxf), 2010; 73(5):573–580.
3.
JavaidM.K., CrozierS.R., HarveyN.C., GaleC.R., DennisonE.M., BoucherB.J., et al.Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet, 2006; 367:36–43.
4.
ColeZ.A., GaleC.R., JavaidM.K., RobinsonS.M., LawC., BoucherB.J., et al.Maternal dietary patterns during pregnancy and childhood bone mass: a longitudinal study. J Bone Miner Res, 2009; 24(3):663–668.
5.
NIH Osteoporosis and Related Bone Diseases – National Resource Center. Osteoporosis in Men. Bethesda, MD: National Institute of Arthritis and Musculoskeletal and Skin Diseases; June 2010. Available at: http://www.niams.nih.gov/Health_info/Bone/Osteoporosis/men.asp. [Accessed October 7, 2010].
6.
AbrahamsenB., BrixenK.Mapping the prescriptiome to fractures in men – a national analysis of prescription history and fracture risk. Osteoporos Int, 2009; 20:585–597.
7.
European Foundation for Osteoporosis and Bone Disease and National Osteoporosis Foundation. Who are candidates for prevention and treatment for osteoporosis?. Osteoporos Int, 1997; 7(1):1–6.
8.
JohnellO., KanisJ.A.An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 2006; 17:1726–1733.
9.
GullbergB., JohnellO., KanisJ.A.World-wide projections for hip fracture. Osteoporos Int, 1997; 7(5):407–413.
10.
ChieW.C., YangR.S., LiuJ.P., TsaiK.S.High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int, 2004; 15:998–1002.
11.
National Osteoporosis Foundation. Fast Facts. Washington, DC: National Osteoporosis Foundation; 2010. Available at: http://www.nof.org/node/40 [Accessed October 7, 2010].
12.
CooperC., CampionG., MeltonL.Hip fracture in the elderly: a worldwide projection. Osteoporos Int, 1992; 2:285–289.
13.
CooperC., MeltonL.J.Epidemiology of osteoporosis. Trends Endocrinol Metab, 1992; 3:224–229.
14.
OrwollE.Osteoporosis in men. Endocrinol Metab Clin North Am, 1998; 27:349–367.
15.
AminS., FelsonD.T.Osteoporosis in men. Rheum Dis Clin North Am, 2001; 27:19–47.
16.
GruntmanisU.Male osteoporosis: deadly, but ignored. Am J Med Sci, 2007; 333:85–92.
17.
ForsenL., SoggardA.J., MeyerH.E., EdnaT., KopjarB.Survival after hip fracture: short and long term excess mortality according to age and gender. Osteoporos Int, 1999; 10:73–78.
18.
FeldsteinA.C., NicholsG., OrwollE., ElmerP.J., SmithD.H., HersonM., et al.The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int, 2005; 16(8):953–962.
19.
CauleyJ.A., FullmanR.L., StoneK.L., ZmudaJ.M., BauerD.C., Barrett-ConnorE., et al.Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int, 2005; 16(12):1525–1537.
20.
DiazM.N., ONeillT.W., SilmanA.J.The influence of family history on hip fractures on the risk of vertebral deformity in men and women: the European vertebral Osteoporosis Study. Bone, 1997; 20:145–149.
21.
SeemanE., MeltonL.J.3rd, O’FallonW.M., RiggsB.L.Risk factors for spinal osteoporosis in men. Am J Med, 1983; 75:977–983.
22.
HaneyE.M., ChanB.K., DiemS.J., EnsrudK.E., CauleyJ.A., Barrett-ConnorE., et al.Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med, 2007; 167:1246–1251.
23.
CampionJ., MaricicM.Osteoporosis in men. Am Fam Phys, 2003; 67(7):1521–1526.
24.
YangY.X., LewisJ.D., EpsteinS., MetzD.C.Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA, 2006; 296(24):2947–2953.
25.
VestergaardP., RejnmarkL., MosekildeL.Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int, 2006; 79:76–83.
26.
TargownikL.E., LixL.M., MetgeC.J., PriorH.J., LeungS., LeslieW.D.Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ, 2008; 179(4):319–326.
27.
TargownikL.E., LixL.M., LeungS., LeslieW.D.Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology, 2010; 138:896–904.
28.
CorleyD.A., KuboA., ZhaoW., QuesenberryC.Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology, 2010; 139(1):93–101.
29.
RouxC.Osteoporosis in inflammatory joint diseases. Osteoporos Int, 2010; Jun 15: (Epub Ahead of Print).[Accessed October 7, 2010].
30.
CoinA., SergiG., MarinS., VianelloA., PerissinottoE., SartiS., et al.Predictors of low bone mineral density in elderly males with chronic obstructive pulmonary disease: the role of body mass index. Aging Male, 2010; 13(2):142–147.
31.
KimB.J., LeeS.H., BaeS.J., KimH.K., ChoeJ.W., KimH.Y., et al.The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. Clin Endocrinol, 2010; 73(3):396–403.
32.
GrecoE.A., FornariR., RossiF., SantiemmaV., ProssomartiG., AnnosciaC., et al.Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract, 2010; 64(6):817–820.
33.
RussellM., MendesN., MillerK.K., RosenC.J., LeeH., KlibanskiA., et al.Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab, 2010; 95(3):1247–1255.
34.
AminS., ZhangY., SawinC.T., EvansS.R., HannanM.T., KielD.P., et al.Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med, 2000; 133:951–963.
35.
ShepherdA.J., CassA.R., RayL.Determining risk of vertebral osteoporosis in men: validation of the male osteoporosis risk estimation score. J Am Board Fam Med, 2010; 23(2):186–194.
36.
World Health Organization. Welcome to FRAX. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases. Available at: http://www.sheffield.ac.uk/FRAX/Accessed October 7, 2010.
Centers for Medicare & Medicaid Services. The Guide to Medicare Preventive Services, 3rd edn. Medicare and Medicaid Program Instructions. Washington, DC: Centers for Medicare & Medicaid Services; Medicare learning Network; Department of Health & Human Services; July 9, 2009. Available at: http://www.cms.gov/MLNProducts/downloads/mps_guide_web-061305.pdf [Accessed July 15, 2010].
39.
LeeH.D., HwangH.F., LinM.R.Use of quantitative ultrasound for identifying low bone density in older people. J Ultrasound Med, 2010; 29(7):1083–1092.
40.
KiebzakG.M., BeinartG.A., PerserK., AmbroseC.G., SiffS.J., HeggenessM.H.Undertreatment of osteoporosis in men with hip fracture. Arch Int Med, 2002; 162:2217–2222.
41.
MadsenH., BrixenK., HallasJ.Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database study. Clin Respir J, 2010; 4(1):22–29.
42.
KimH.S., FreedlandS.J.Androgen deprivation therapy in prostate cancer: anticipated side effects and their management. Curr Opin Support Palliat Care, 2010; 4(3):147–152.
43.
SmithM.R., McGovernF.J., ZietmanA.L., FallonM.A., HaydenD.L., SchoenfeldD.A., et al.Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 2001; 345:948–955.
44.
CastleE.P., LangenstroerP., ThrasherJ.B.Common complications of androgen deprivation therapy for prostate cancer. AUA Update Series, 2003; 22:106–112.
45.
ItoK., ElkinE.B., GirotraM., MorrisM.J.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med, 2010; 152(10):621–629.
46.
SaylorP.J., KaufmanD.S., MichaelsonM.D., LeeR.J., SmithM.R.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol, 2010; 183(6):2200–2205.
47.
van den BerghJ., van GeelT., GeusensP.Should the vitamin D level be determined for all fracture patients?. Ned Tijdschr Geneeskd, 2010; 154:A1758.
48.
OrwollE., MillerP.D., AdachiJ.D., BrownJ., AdlerR.A., KendlerD., et al.Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized multicenter double blind active controlled study. J Bone Miner Res, 2010; 25(10):2239–2250.
49.
JohnsonDA, WilliamsMI, PetkovVI, AdlerRA. Zoledronic acid treatment of osteoporosis: effects in men. Endocr Pract, 2010; May 24: 1–23 [Epub ahead of print]
50.
MaricicM.Intravenous zoledronic acid: what are the indications for male osteoporosis?. Curr Osteoporos Rep, 2010; 8(1):4–9.
51.
CampbellS.C., BhoopalamN., MoritzT.E., PandyaM., IyerP., VanveldhuizenP., et al.The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology, 2010; 75(5):1138–1143.
52.
MiyauchiA., MatsumotoT., SugimotoT., TsujimotoM., WarnerM.R., NakamuraT.Effects of teiparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24 month clinical study: 12 month, randomized placebo controlled double blind and 12 month open label phases. Bone, 2010 Sep;47(3):493–502.
53.
VestergaardP, RejnmarkL, MosekildeL.Risk of fractures associated with treatment for benign prostate hyperplasia in men. Osteoporos Int, 2010; June 15: (Epub ahead of print) [Accessed on October 7, 2010].
54.
AubertR.E., HerreraV., ChenW., HaffnerS.M., PendergrassM.Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab, 2010; 12(8):716–721.
55.
ValmadridC., VoorheesC., LittB., SchneyerC.R.Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol, 2001; 58:1369–1374.
56.
Anon. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum, 2001; 44:1496-503.
57.
KukuljanS., NowsonC.A., BassS.L., SandersK., NicholsonG.C., SeibelM.J., et al.Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial. Osteoporos Int, 2009; 20(7):1241–1251.
58.
CornuzJ., FeskanichD., WillettW.C., ColditzG.A.Smoking, smoking cessation and risk of hip fracture in women. Am J Med, 1999; 106(3):311–314.
World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report. Brussels: WHO; 2004. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf [Accessed October 2010].
QaseemA., SnowV., ShekelleP., HopkinsR.Jr., ForcieaM.A., OwensD.K., et al.Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2008; 148:680–684.
63.
BrownJ., JosseR.G.Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ, 2002; 167(10 Suppl):S1–34.
